Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema

Abstract

Purpose:

To investigate the relations of vascular endothelial growth factor, growth factors, soluble vascular endothelial growth factor receptors, and inflammatory factors to recurrence of macular edema after anti-vascular endothelial growth factor therapy in patients with branch retinal vein occlusion.

Methods:

This study retrospectively investigated 17 patients with branch retinal vein occlusion who received intravitreal ranibizumab injection three times within 6 months for recurrent macular edema. Aqueous humor samples were obtained from these patients at every recurrence. Levels of soluble vascular endothelial growth factor receptor-1, soluble vascular endothelial growth factor receptor-2, vascular endothelial growth factor, placental growth factor, platelet-derived growth factor-AA, soluble intercellular adhesion molecule-1, monocyte chemoattractant protein-1, interleukin-6, interleukin-8, interleukin-12(p70), and interleukin-13 were measured by the suspension array method. Aqueous flare values were measured with a laser flare meter and central macular thickness was determined by optical coherence tomography.

Results:

Mean best-corrected visual acuity and central macular thickness improved significantly over time after intravitreal ranibizumab injection, but the aqueous flare value at recurrence after intravitreal ranibizumab injection showed no significant change compared with baseline. Aqueous humor levels of soluble vascular endothelial growth factor receptor-1, soluble vascular endothelial growth factor receptor-2, vascular endothelial growth factor, platelet-derived growth factor-AA, monocyte chemoattractant protein-1, and interleukin-8 decreased significantly over time after intravitreal ranibizumab injection. However, there were no significant changes of the other five factors/cytokines (placental growth factor, soluble intercellular adhesion molecule-1, interleukin-6, interleukin-12, and interleukin-13) at recurrence after intravitreal ranibizumab injection compared with baseline.

Conclusion:

These findings suggest that persistent inflammation may influence the recurrence of macular edema in branch retinal vein occlusion patients, and that adding steroid therapy might be an effective strategy for preventing recurrence.

Keywords

Cytokines branch retinal vein occlusion recurrence of macular edema ranibizumab

Get full access to this article

View all access options for this article.

References

Gutman

Zegarra

The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974; 78(2): OP178–OP192.

McIntosh

Mohamed

Saw

, et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007; 114(5): 835–854.

Noma

Funatsu

Yamasaki

, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140(2): 256–261.

Noma

Minamoto

Funatsu

, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006; 244(3): 309–315.

Brown

Campochiaro

Bhisitkul

, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118(8): 1594–1602.

Heier

Campochiaro

Yau

, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119(4): 802–809.

Campochiaro

Sophie

Pearlman

, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014; 121(1): 209–219.

Hoeh

Ach

Schaal

, et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009; 247(12): 1635–1641.

Ach

Hoeh

Schaal

, et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010; 248(2): 155–159.

10.

Hanada

Iijima

Sakurada

, et al. Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab. Jpn J Ophthalmol 2012; 56: 165–174.

11.

Noma

Mimura

Shimada

Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. BMC Ophthalmol 2014; 14: 67.

12.

Noma

Mimura

Yasuda

, et al. Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci 2014; 55(6): 3878–3885.

13.

Tsujikawa

Sakamoto

Ota

, et al. Serous retinal detachment associated with retinal vein occlusion. Am J Ophthalmol 2010; 149: 291–301. e5.

14.

Clauss

Weich

Breier

, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271(30): 17629–17634.

15.

Barleon

Sozzani

Zhou

, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87(8): 3336–3343.

16.

Hiratsuka

Minowa

Kuno

, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1988; 95: 9349–9354.

17.

Murakami

Zheng

Hirashima

, et al. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler Thromb Vasc Biol 2008; 28(4): 658–664.

18.

Tsujikawa

Ogura

Hiroshiba

, et al. In vivo evaluation of leukocyte dynamics in retinal ischemia reperfusion injury. Invest Ophthalmol Vis Sci 1998; 39(5): 793–800.

19.

Tolentino

Miller

Gragoudas

, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103(11): 1820–1828.

20.

Campochiaro

Wykoff

Shapiro

, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014; 121(9): 1783–1789.

21.

Shibuya

Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2(12): 1097–1105.

22.

Ledebur

Parks

TP.

Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. J Biol Chem 1995; 270(2): 933–943.

23.

Baldwin

Jr.

The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649–683.

24.

Marumo

Schini-Kerth

Fisslthaler

, et al. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 1997; 96(7): 2361–2367.

25.

Hossain

Boynton

AL.

Rapid disruption of gap junctional communication and phosphorylation of connexin43 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptor. J Cell Physiol 1998; 174(1): 66–77.

26.

Mamer

Chen

Weddell

, et al. Discovery of high-affinity PDGF-VEGFR interactions: redefining RTK dynamics. Sci Rep 2017; 7(1): 16439.

27.

Fan

Wang

, et al. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion. Curr Eye Res 2014; 39(9): 938–943.

28.

Noma

Mimura

Yasuda

, et al. Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab. Br J Ophthalmol 2017; 101(2): 180–185.

29.

Matsumoto

Suzuma

Yamada

, et al. Retinal blood flow after intravitreal bevacizumab is a predictive factor for outcomes of macular edema associated with central retinal vein occlusion. Retina 2018; 38(2): 283–291.

30.

Lin

Dib

, et al. Cholesterol crystals induce inflammatory cytokines expression in a human retinal pigment epithelium cell line by activating the NF-κB pathway. Discov Med 2014; 18: 7–14.